

FUNGAL INFECTION

Title: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) (COG ACCL0933)

Purpose: To determine if using Caspofungin (also called Cancidas®) will be better than the current standard antifungal drug fluconazole at preventing invasive fungal infections when given to people with AML after receiving chemotherapy treatment.

Eligibility: Patients between 3 and 30 years of age with:

-Newly diagnosed de novo AML

-First or subsequent relapse of AML

-Secondary AML

-Treatment with institutional standard AML therapy in those without AML (for example myelodysplastic syndrome, bone marrow blasts > 5% or biphenotypia).

Principal Investigator: [Joseph M. Wiley, M.D.](#)

Phase: III

For more information, contact: Stephanie Entrup

Telephone Number: 410-601-8393

Email: sentrup@lifebridgehealth.org